Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)

被引：0

作者：

Jove, M. ^{[1
]}

Brana, I. ^{[2
]}

Oliva Bernal, M. ^{[3
]}

Hernando-Calvo, A. ^{[4
]}

Erasun Lecuona, C. ^{[5
]}

Assaf Pastrana, J. D. ^{[6
]}

Bazan Peregrino, M. ^{[7
]}

Mato-Berciano, A. ^{[8
]}

Maliandi, M. V. ^{[8
]}

Torres-Manjon, S. ^{[9
]}

Martinez De Villareal, J. ^{[10
]}

Real, F. X. ^{[11
]}

Nuciforo, P. G. ^{[12
]}

Alemany, R. ^{[13
]}

Capella, G. ^{[14
]}

Blasi, E. ^{[15
]}

Blasco, C. ^{[16
]}

Cascallo Piqueras, M. ^{[17
]}

Mesia Nin, R. ^{[18
]}

机构：

[1] Hosp Duran & Reynals, Med Oncol, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain

[2] Vall dHebron Univ Hosp, Mol Therapeut Res Unit, Barcelona, Spain

[3] Hosp Duran & Reynals, Div Med Oncol, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Barcelona, Spain

[4] Vall dHebron Inst Oncol VHIO, Mol Therapeut Res Unit, Early Drug Dev Unit, La Caixa Res UITM, Barcelona, Spain

[5] Hosp Duran & Reynals, Oncol Dept, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain

[6] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain

[7] VCN Biosci SL, R&D, Barcelona, Spain

[8] VCN Biosci SL, R&D, Sant Cugat Del Valles, Spain

[9] IDIBELL, Catalan Inst Oncol ICO, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Barcelona, Spain

[10] CNIO Ctr Nacl Invest Oncol, Epithelial Carcinogenesis Grp, Madrid, Spain

[11] CNIO Ctr Nacl Invest Oncol, Epithelial Carcinogenesis Grp, Mol Oncol Programme, Madrid, Spain

[12] Vall dHebron Inst Oncol VHIO, Mol Oncol Dept, Cellex Ctr, Barcelona, Spain

[13] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Spain

[14] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Hereditary Canc Program, Lhospitalet De Llobregat, Spain

[15] VCN Biosci SL, Regulatory, Sant Cugat Del Valles, Spain

[16] VCN Biosci SL, Clin Operat, Barcelona, Spain

[17] VCN Biosci SL, Clin Res, Barcelona, Spain

[18] Hosp Duran & Reynals, ICO Inst Catala Oncol, Dept Med Oncol, Lhospitalet De Llobregat, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1231P

引用

页码：S1112 / S1112

页数：1

共 50 条

[1] VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial
Jove, M.
Brana, I.
Taberna, M.
Hernando-Calvo, A.
Brenes Castro, J.
Garralda, E.
Plana Serrahima, M.
Manos Pujol, M.
Capella, G.
Alemany, R.
Blasi, E.
Blasco, C.
Cascallo Piqueras, M.
Nin, R. Mesia
ANNALS OF ONCOLOGY, 2019, 30 : 47 - 47
[2] Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/ metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment
Jove, M.
Brana, I.
Oliva Bernal, M.
Hernando Calvo, A.
Erasun Lecuona, C.
Assaf Pastrana, J. D.
Mato-Berciano, A.
V. Maliandi, M.
Torres-Manjon, S.
Moreno, R.
Le, C.
G. Nuciforo, P.
Alemany, R.
Capella, G.
Blasco, C.
Cascallo Piqueras, M.
Mesia Nin, R.
ANNALS OF ONCOLOGY, 2023, 34 : S589 - S590
[3] Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment
Jove, M.
Brana, I.
Oliva Bernal, M.
Hernando Calvo, A.
Erasun Lecuona, C.
Assaf Pastrana, J. D.
Mato-Berciano, A.
Maliandi, M. V.
Torres-Manjon, S.
Moreno, R.
Le, C.
Nuciforo, P. G.
Alemany, R.
Capella, G.
Blasco, C.
Cascallo Piqueras, M.
Mesia Nin, R.
ANNALS OF ONCOLOGY, 2023, 34 : S589 - S589
[4] Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Siu, Lillian L.
Papadopoulos, Kyriakos P.
Tsai, Frank Yung-Chin
Hansen, Aaron Richard
Robbins, Paul B.
Li, Xia
Lai, Dominic W.
Blake-Haskins, John A.
Fury, Matthew G.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[5] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
Shi, Y-K.
Gao, L.
Tian, Y.
Chen, J.
Wang, J.
Bai, C.
Li, X.
Su, H.
Liu, Z.
ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
[6] Phase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent ormetastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE
Licitra, L.
Even, C.
Haddad, R.
Tahara, M.
Goswami, T.
Franks, A.
Emeribe, U.
Jarkowski, A., III
Melillo, G.
Ferris, R. L.
ANNALS OF ONCOLOGY, 2015, 26 : 101 - 101
[7] A phase I study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of MEDI0562 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Leidner, Rom Samuel
Patel, Sandip Pravin
Fury, Matthew G.
Ferris, Robert L.
McDevitt, Jennifer T.
Lanasa, Mark C.
Glisson, Bonnie S.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis
Richa, T.
Johnson, M.
Cognetti, D. M.
Argiris, A.
Luginbuhl, A.
Zinner, R.
Axelrod, R.
Bar-Ad, V.
Goldman, R.
Rodeck, U.
Martinez-Outschoorn, U.
Curry, J. M.
ANNALS OF ONCOLOGY, 2019, 30
[9] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Dunn, Lara
Ho, Alan Loh
Eng, Juliana
Michel, Loren S.
Fetten, James Vincent
Warner, Elizabeth
Kriplani, Anuja
Zhi, Wanqing Iris
Ng, Kenneth K.
Haque, Sofia
Pfister, David G.
Sherman, Eric Jeffrey
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV plus R/M HNSCC)
Aggarwal, C.
Saba, N. F.
Algazi, A. P.
Sukari, A.
Seiwert, T.
Haigentz, M.
Porosnicu, M.
Bonomi, M.
Boyer, J.
Durham, N.
Kumar, R.
Laubscher, K.
Gong, M.
Ceaicovscaia, N.
Hernandez, A. Gasco
ANNALS OF ONCOLOGY, 2020, 31 : S661 - S662

← 1 2 3 4 5 →